-continued

```
<223> OTHER INFORMATION: Glu or Asp

<400> SEQUENCE: 55

Glu Ile Arg Ser Xaa Ser Asp Xaa Xaa Ala Thr Xaa Tyr Ala Xaa Ala
1               5                   10                  15

Val Lys Gly


<210> SEQ ID NO 56
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      6xHis tag

<400> SEQUENCE: 56

His His His His His His
1               5


<210> SEQ ID NO 57
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      peptide

<400> SEQUENCE: 57

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1               5                   10                  15
```

We claim:

1. A humanized monoclonal anti-Calcitonin Gene-Related Peptide (CGRP) antagonist antibody, comprising:

two human IgG heavy chains, each heavy chain comprising three complementarity determining regions (CDRs) and four framework regions, wherein portions of the two heavy chains together form an Fc region; and

two light chains, each light chain comprising three CDRs and four framework regions;

wherein the CDRs impart to the antibody specific binding to a CGRP consisting of amino acid residues 1 to 37 of SEQ ID NO:15 or SEQ ID NO: 43.

2. The antibody of claim **1**, wherein constant regions of the IgG heavy chains are IgG1 constant regions.

3. The antibody of claim **2**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

4. The antibody of claim **2**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

5. The antibody of claim **2**, wherein a constant region of at least one IgG heavy chain comprises a mutation in an oligosaccharide attachment amino acid residue that is part of an N-glycosylation recognition sequence in the constant region.

6. The antibody of claim **1**, wherein the IgG constant regions are IgG2 constant regions.

7. The antibody of claim **6**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

8. The antibody of claim **6**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 33 to 37 of SEQ ID NO:15.

9. The antibody of claim **6**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

10. The antibody of claim **6**, wherein a constant region of at least one IgG heavy chain comprises a mutation in an oligosaccharide attachment amino acid residue that is part of an N-glycosylation recognition sequence in the constant region.

11. The antibody of claim **1**, wherein constant regions of the IgG heavy chains are IgG4 constant regions.

12. The antibody of claim **11**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

13. The antibody of claim **11**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

14. The antibody of claim **11**, wherein a constant region of the antibody comprises a mutation in an oligosaccharide attachment amino acid residue that is part of an N-glycosylation recognition sequence in the constant region.

15. The antibody of claim **14**, wherein the antibody is aglycosylated at the mutation position.

* * * * *